Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of biomarker for preparing medicine for predicting feedback response of 5-aminosalicylic acid in treatment of ulcerative colitis

An ulcerative colitis, biomarker technology, applied in the field of biomedicine, can solve the problems of no feedback response, unclear pathophysiology and other factors, and achieve the effect of disease control

Active Publication Date: 2013-06-12
HAYAO CIHANG PHARM CO LTD +1
View PDF4 Cites 12 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

But to date, no relevant biomarkers and systems are available to determine the feedback response when treating UC patients with 5-ASA
[0006] As shown above, one of the mainstays of conventional treatment for UC is the use of 5-ASA, but the efficacy of 5-ASA in the treatment of active UC is only 30-40%
UC pathophysiology and other factors affecting response to 5-ASA therapy are not well understood

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of biomarker for preparing medicine for predicting feedback response of 5-aminosalicylic acid in treatment of ulcerative colitis
  • Application of biomarker for preparing medicine for predicting feedback response of 5-aminosalicylic acid in treatment of ulcerative colitis
  • Application of biomarker for preparing medicine for predicting feedback response of 5-aminosalicylic acid in treatment of ulcerative colitis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0057] The present invention provides sex-dependent serum target biomarkers. When a patient uses one or more biomarkers to show a level different from the normal level, it can be predicted that 5-ASA will be used to treat different colon sites (left hemicolitis, Proctosigmoid colitis, pancolitis and extensive colitis) in patients with mild to moderate UC.

[0058] 5-ASA does not respond to the application of serum biomarkers in personalized clinical practice

[0059] As mentioned above, 60% of clinical failures are encountered when using 5-ASA to treat patients with moderate UC, and 80% of clinical failures are encountered when using placebo. Due to a lack of understanding of the pathophysiology of the disease, 5-ASA therapy does not take into account differences in gender and the location of the lesion in the colon. Personalized drug treatment based on the development of clinical biomarkers will provide more effective treatment options that take into account the individual. In t...

Embodiment 2

[0070] Used to predict 5-ASA response in female patients with left hemicolitis. First determine a patient who has been diagnosed with left hemicolitis, and then confirm the diagnosis of left hemicolitis by routine colonoscopy. Usually, 5-ASA is prescribed to patients as a routine drug in the treatment of left hemicolitis. Before treating the patient’s colitis, the clinician will check one or more blood samples and obtain the samples, then prepare the serum, and finally use the above-mentioned appropriate 5-ASA non-responsive target biomarkers to determine its correlation s level. The measured target biomarker level is compared with the standard value shown in Table 2, and the result is the prediction of the efficacy of 5-ASA (the dose is 2.4 g 5-ASA / day and 4.8 g 5-ASA / day , The efficacy of treating female patients with left hemicolitis in a 6-week course of treatment). For example, if the patient's specific 5-ASA does not respond to the target biomarker and the level of the...

Embodiment 3

[0077] Methods and systems for predicting 5-ASA response in male patients with left hemicolitis. First determine a patient who has been diagnosed with left hemicolitis, and then confirm the diagnosis of left hemicolitis by routine colonoscopy. Usually, 5-ASA is prescribed to patients as a routine drug in the treatment of left hemicolitis. Before treating the patient’s colitis, the clinician will check one or more blood samples and obtain the samples, then prepare the serum, and finally use the above-mentioned appropriate 5-ASA non-responsive target biomarkers to determine its correlation s level. The measured target biomarker level is compared with the standard value shown in Table 3, and the result is the prediction of the efficacy of 5-ASA (the dose is 2.4 g 5-ASA / day and 4.8 g 5-ASA / day , The efficacy of treating male patients with left hemicolitis in a 6-week course of treatment). For example, if the patient's specific 5-ASA does not respond to the target biomarker and t...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of a biomarker for preparing a medicine for predicting feedback response of 5-aminosalicylic acid in treatment of ulcerative colitis. The biomarker determined in the invention is the basis of a target biomarker associated with gender difference response when 5-aminosalicylic acid (5-ASA) is used to treat ulcerative colitis (UC). The biomarker comprises a group of protein biomarkers which can differentiate response difference for treatment by 5-ASA between different genders and determine the curative effect by using 5-ASA under different UC conditions. Meanwhile, a novel drug target for a UC novel curative method is effectively determined and verified by using the biomarker with specificity for genders and disease focus parts, novel diagnostic reagents, medicines, methods and diagnostic standards are developed, and the application is used for establishing a UC treatment policy.

Description

Technical field [0001] The invention belongs to the field of biomedicine technology, and specifically relates to the application of biomarkers in the preparation of a feedback response drug for predicting 5-aminosalicylic acid in the treatment of ulcerative colitis. Background technique [0002] Ulcerative colitis (UC, referred to as ulcer) is a recurrent inflammatory bowel disease (IBD) that occurs in the large intestine or colon. UC patients usually show the same symptoms as patients with irritable bowel syndrome (IBS), but the condition of IBS patients is milder, which also makes the diagnosis of UC very complicated. Similarly, the patient's uncertain colitis may not be ulcerative colitis, but more similar to another inflammatory bowel disease, Croce's colitis. [0003] From an anatomical point of view, the symptoms of each UC patient are different. The lesion can be located only in the sigmoid colon, or it can extend to the entire colon. Initially, UC patients were mainly tre...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): G01N33/96
Inventor 段燕文王锋布鲁斯·亚克欣
Owner HAYAO CIHANG PHARM CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com